BLFS — BioLife Solutions Share Price
- $1.16bn
- $1.16bn
- $143.27m
- 69
- 22
- 95
- 64
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 3.61 | ||
Price to Tang. Book | 14.98 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 9.57 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -14.21% | ||
Return on Equity | -16% | ||
Operating Margin | -40.35% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 27.37 | 48.09 | 119.16 | 161.76 | 143.27 | 110.41 | 119.83 | 48.65% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Its expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage and distribution. Its biopreservation media products, HypoThermosol FRS and CryoStor Freeze Media, are formulated to mitigate preservation-induced, delayed-onset cell damage and death which result when cells and tissues are subjected to reduced temperatures. Its bioproduction tools portfolio includes human platelet lysates for cell expansion. It is a provider of biological and pharmaceutical storage and cold chain logistics. Its monitoring systems allow customers real time tracking of the storage temperatures of their materials throughout the logistics process. It operates about five storage facilities in the United States and one facility in the Netherlands.
Directors
- Michael Rice CHM (58)
- Roderick de Greef PRE (60)
- Troy Wichterman CFO
- Aby Mathew EVP (49)
- Todd Berard CMO (52)
- Sarah Aebersold VPR (46)
- Karen Foster OTH (61)
- Marcus Schulz OTH (43)
- Amy DuRoss IND (47)
- Rachel Ellingson IND (51)
- Joydeep Goswami IND (49)
- Joseph Schick IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- March 25th, 1998
- Public Since
- November 22nd, 1989
- No. of Shareholders
- 256
- No. of Employees
- 409
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 46,138,201
- Address
- SUITE 310, 3303 MONTE VILLA PARKWAY, BOTHELL, 98021
- Web
- https://www.biolifesolutions.com/
- Phone
- +1 4254011400
- Contact
- Troy Wichterman
- Auditors
- BDO USA, LLP
Upcoming Events for BLFS
Q4 2024 BioLife Solutions Inc Earnings Release
Similar to BLFS
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
As of Today at 20:04 UTC, shares in BioLife Solutions are trading at $25.12. This share price information is delayed by 15 minutes.
Shares in BioLife Solutions last closed at $25.12 and the price had moved by +84.03% over the past 365 days. In terms of relative price strength the BioLife Solutions share price has outperformed the S&P500 Index by +45.57% over the past year.
The overall consensus recommendation for BioLife Solutions is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBioLife Solutions does not currently pay a dividend.
BioLife Solutions does not currently pay a dividend.
BioLife Solutions does not currently pay a dividend.
To buy shares in BioLife Solutions you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $25.12, shares in BioLife Solutions had a market capitalisation of $1.16bn.
Here are the trading details for BioLife Solutions:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BLFS
Based on an overall assessment of its quality, value and momentum BioLife Solutions is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in BioLife Solutions is $27.89. That is 11.03% above the last closing price of $25.12.
Analysts covering BioLife Solutions currently have a consensus Earnings Per Share (EPS) forecast of -$0.55 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioLife Solutions. Over the past six months, its share price has outperformed the S&P500 Index by +32.75%.
As of the last closing price of $25.12, shares in BioLife Solutions were trading +30.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BioLife Solutions PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $25.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BioLife Solutions' management team is headed by:
- Michael Rice - CHM
- Roderick de Greef - PRE
- Troy Wichterman - CFO
- Aby Mathew - EVP
- Todd Berard - CMO
- Sarah Aebersold - VPR
- Karen Foster - OTH
- Marcus Schulz - OTH
- Amy DuRoss - IND
- Rachel Ellingson - IND
- Joydeep Goswami - IND
- Joseph Schick - IND